ORYZON Raises $19 Million in Private Placement to Advance Therapeutic Programs
4.9 million new shares issued at a price of 3.39 euros per share The company is valued at $110 million The new shareholders include CEO of Active Motif, a US epigenetics company, also a founder of Invitrogen The Company expects to list on the Madrid Stock …